A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom

Palivizumab is cost-effective compared to no prophylaxis in the United Kingdom in many of the subgroups considered, showing that palivizumab would be a cost-effective use of National Health Service resources. </AbstractSection> Copyright Bentley et al.; licensee Springer. 2013

MoreLess

Year of publication:	2013
Authors:	Bentley, Anthony ; Filipovic, Ivana ; Gooch, Katherine ; Büsch, Katharina
Published in:	Health Economics Review. - Springer. - Vol. 3.2013, 1, p. 1-12
Publisher:	Springer
Subject:	Palivizumab \| Prophylaxis \| Cost-effectiveness \| Respiratory syncytial virus \| United Kingdom

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://ebvufind01.dmz1.zbw.eu/10010998810